However, recognizing that a randomized clinical trial would likely be anachronistic and unfeasible, our pooled analysis provides the best evidence available in favor of the addition of an anti-angiogenic to chemotherapy in the second-line treatment of BRAF-mutant CRC. This evidence concerns the gene BRAF and colorectal carcinoma.